The use of modern dopamine partial agonists in bipolar depression: is the evidence sound?

Curr Med Res Opin. 2022 May;38(5):773-775. doi: 10.1080/03007995.2022.2059973. Epub 2022 Apr 12.

Authors

Gianluca Serafini^{1

2}, Henry A Nasrallah³, Mario Amore^{1

2}

Affiliations

¹ Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health DINOGMI, Section of Psychiatry, University of Genoa, Genoa, Italy.
² IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
³ University of Cincinnati, Ohio, USA.

PMID: 35361016
DOI: 10.1080/03007995.2022.2059973

No abstract available

Publication types

Editorial

MeSH terms

Antipsychotic Agents* / therapeutic use
Bipolar Disorder* / drug therapy
Dopamine / therapeutic use
Dopamine Agonists / adverse effects
Humans
Piperazines / therapeutic use

Substances

Antipsychotic Agents
Dopamine Agonists
Piperazines
Dopamine